Cancer imposes a huge burden on society and has been identified as the leading cause of death in both more and less economically developed countries [13]. In 2012, the International Agency for Research on Cancer (IARC) estimated that there were approximately 14 million new cancer cases and 8.2 million cancer deaths worldwide. By 2030, considering the growth and aging of the world population, 22 million new cancer cases and 13 million cancer deaths are expected annually. Due to changes in lifestyle such as smoking habits, poor diet, physical inactivity, and fewer childbirths, the future cancer burden will probably be even worse in economically developing countries.

We have conducted a variety of joint research and experiments with Kagoshima University and Kyushu University in our attempt to discover the cancer stopping effects and other efficacy of fucoidan, and have shared the research results and information.

[Kagoshima University] [Kyushu University]

[Our focus in our research] 
・Discovering cancer suppression effects of fucoidan mixed foods : By animal experiments and clinical application 
・Discovering cancer inhibitory effects of fucoidan mixed foods 
・Discovering effects of fucoidan mixed foods in terms of obesity suppression, high blood glucose suppression, anti-tumor effect and natural killer (NK) activity enhancing capacity

Founded in 1988 on a personalized, patient-centered approach to cancer care, Cancer Treatment Centers of America® (CTCA) is dedicated to tailoring a combination of cancer treatments to the needs of each individual patient. From genomic tumor assessments to state-of-the-art technologies and evidence-informed supportive therapies that target cancer-related side effects, comprehensive services are delivered by a team of cancer experts, all under one roof.

Inherent in this integrative approach is a commitment to personalized medicine, tapping breakthroughs in genomic testing, precision cancer treatment and other scientific advances to offer patients as many options as possible. Our oncologists, nurses and other clinicians offer a level of expertise that comes with working exclusively with cancer patients. Cancer treatment is all we do.

Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 47 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.

The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and biomedical research around the world.

Cladosiphon okamuranus (Chordariales, Phaeophyceae),5 Okinawa mozuku in Japanese, is one of the important edible seaweeds. In Okinawa, C. okamuranushas been cultivated for more than 35 years by several fishermen’s associations, including those in Onna and Chinen Villages. This cultivation history has established several strains of mozuku that have similar morphology and texture. It was reported in the 36th annual report of the Japanese Cabinet Office that approximately 20 kilotons of mozuku (C. okamuranus and Nemacystus decipiens (‘Itomozuku’)) are produced annually, yielding approximately 4 billion Japanese yen in 2006. In addition, C. okamuranus and N. decipiens are sources of fucoidan,6 a sulfated polysaccharide found in the cell-wall matrix of brown algae that has anti-coagulant, anti-thrombin-like, and tumor-suppressant activities.7 Brown algae also produce alginates.8,9